JLL Receives Frost & Sullivan's 2026 North American Competitive Strategy Leadership Recognition for Facility Management
JLL is recognized for transforming facility management through an integrated Workplace Management platform, digital innovation, and sector-focused execution that strengthens operational resilience and business performance.
BlackRock Declares Quarterly Dividend of $5.73 on Common Stock
BlackRock, Inc. (NYSE:BLK) today announced that its Board of Directors has declared a quarterly cash dividend of $5.73 per share of common stock, payable December 22, 2026 to shareholders of record at the close of business on December 8, 2026. About BlackRock BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate. View source version on businesswire.com: https://www.businessw
Walker & Dunlop Arranges $270 Million Refinancing for Nasser Freres’ The Greyson in Jersey City
Walker & Dunlop, Inc. announced today that it has arranged $270,000,000 in refinancing for The Greyson, a 28-story, 622-unit, Class A mixed-use residential tower developed by Nasser Freres in the heart of Jersey City's Journal Square neighborhood. The financing marks a significant milestone for the development, supporting its transition from construction to stabilized operations and positioning the property for long-term success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118022862/en/The Greyson. Photo credits: Nasser Freres Walker & Dunlop Capital Markets Institutional Advisory served as exclusive advisor to Nasser Frer
Everforth, Inc. Announces Withdrawal of Proposed Senior Notes Offering
Everforth, Inc. (NYSE:EFOR) ("Everforth") announced today that it has withdrawn its previously proposed offering of $500 million in aggregate principal amount of senior notes due 2031 as a result of market conditions. The proposed transaction was opportunistic to refinance the Company’s existing 4.625% senior notes well in advance of their May 2028 maturity. While Everforth had meaningful investor interest, the Company made the strategic decision to withdraw the offering as the terms do not reflect the strength of its business. Everforth’s strong free cash flow and liquidity position provide the Company with significant financial flexibility. Everforth remains committed to using its fre
BlackRock Health Sciences Term Trust (BMEZ) Announces Expiration and Preliminary Results of Tender Offer
BlackRock Health Sciences Term Trust (the "Fund") announced today the expiration and preliminary results of its tender offer ("Tender Offer") for up to 5% of its outstanding common shares (the "Shares"). The Tender Offer commenced on October 16, 2026 and expired at 5:00 p.m. Eastern time on November 18, 2026. Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below. Fund Name Ticker CUSIP Shares Offered for Repurchase Shares Tendered (Preliminary Results) BlackRock Health Sciences Term Trust BMEZ 09260E105 3,125,070 13,178,845 Based on the preliminary results
Century Complete Celebrates Model Home Grand Opening at Cates Bay Crossing in Conway, South Carolina
New community brings 94 homesites to well-connected location 15 miles from Myrtle BeachKEY TAKEAWAYSGrand Opening Details: The Nov. 21 model home Grand Opening at Cates Bay Crossing will feature tours and an appearance from members of Minor League Baseball team, The Myrtle Beach Pelicans. Floor Plans Designed for Real Life: Cates Bay Crossing offers five one- and two-story floor plans priced from the $260s. Select plans feature versatile living spaces such as flex rooms, gamerooms, and private studies. Move-In Ready Options: Cates Bay Crossing features a mix of move-in ready homes and winter move-in homes, for buyers seeking a faster new construction timeline. Thoughtful Included Features: Ev
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in patients with resectable soft tissue sarcoma. Patients with post-treatment tumour-infiltrating lymphocyte (TIL) levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels. Results build on previously reported strong pathological responses and further support the potential of efti-based combination therapy. SYDNEY, A
JOYY Reports Third Quarter 2026 Unaudited Financial Results
JOYY Inc. (NASDAQ:JOYY) ("JOYY" or the "Company"), a global technology company, today announced its unaudited financial results for the third quarter of 2026. Third Quarter 2026 Financial Highlights1 Net revenues were US$624.6 million, an increase of 15.6% from US$540.2 million in the corresponding period of 2025, and an increase of 5.7% from US$590.8 million in the second quarter of 2026. Social Entertainment net revenues increased by 8.8% to US$441.0 million from US$405.5 million in the corresponding period of 2025, and by 4.3% from US$422.7 million in the second quarter of 2026.BIGO Ads net revenues increased by 39.6% to US$145.7 million fr
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition — — Broad-spectrum activity across multiple KRAS mutations, combining inhibition of both ON and OFF states to intercept adaptive resistance —
Enerflex Ltd. (TSX:EFX) (NYSE:EFXT) ("Enerflex" or the "Company") today announced the appointment of Christine Morris as Senior Vice President and Chief Financial Officer, effective January 1, 2027. Ms. Morris will succeed Preet S. Dhindsa, who will step down from his role effective December 31, 2026. Paul Mahoney, Enerflex’s President and Chief Executive Officer, commented: "We thank Preet for his leadership and contributions to Enerflex over the past three years. During his tenure as CFO and period as interim CEO, Enerflex successfully completed the integration of Exterran, strengthened its financial flexibility, and established a soli
Endava plc Investors Have Until November 30th to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Endava (DAVA) To Contact Them Directly To Discuss Their Options If you purchased or acquired Endava securities between September 4, 2025 and September 21, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES QUARTERLY DIVIDEND
Richmond Mutual Bancorporation, Inc. (NASDAQ:RMBI) announced today that its Board of Directors has declared a cash dividend on Richmond Mutual Bancorporation common stock of $0.15 per share. The cash dividend will be payable on December 17, 2026, to stockholders of record as of the close of business on December 3, 2026. Garry Kleer, Chairman and Chief Executive Officer, commented, "As we continue the integration of our two organizations under First Bank Midwest and Richmond Mutual Bancorporation, we are pleased to declare a quarterly cash dividend for our shareholders. Our strong capital position and disciplined approach to financial management p
TIME Names Bloom Energy Among America’s Top Manufacturers of 2027
Bloom Energy (NYSE:BE), a global leader in power solutions, today announced that it has been named to TIME's list of America's Top Manufacturers of 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118727682/en/America's Top Manufacturers of 2027The list, developed by TIME and Statista, recognizes 250 U.S. manufacturers based on financial performance, innovation capacity and employment metrics. Companies were evaluated using measures including revenue growth, research and development investment, workforce growth and retention, and workplace safety."At Bloom, technology and manufacturing innovation go hand in hand," said Satis
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals Livsayis is Regeneron's first approved si
Hy-Vee Health with Oscar Expands Across Iowa, Into Kansas City and Omaha for 2027 Open Enrollment
Individuals and families can shop for Hy-Vee Health with Oscar on HealthCare.gov starting Nov. 1. Hy-Vee, Inc. ("Hy-Vee"), a leading grocery store in the Midwest, and Oscar, one of the fastest-growing insurers in the individual market and part of Oscar Health (NYSE:OSCR), today announced that Hy-Vee Health with Oscar is expanding statewide across Iowa and launching in Kansas City and Omaha for 2027 Open Enrollment.1 Beginning Nov. 1, 2026, individuals and families can enroll in Hy-Vee Health with Oscar directly through HealthCare.gov for 2027 coverage. Employees in CHOICE Arrangements (formerly ICHRA) can also enroll using their tax-free monthly employer contributions. Hy-Vee became j
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium
Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027 Company to host a live webcast on November 19, 2026, at 7:00 a.m.
UGI Corporation Announces Plan to Pursue the Separation of Its Global Liquefied Petroleum Gas Business Into a Standalone Public Company
Planned Separation Intended to Unlock Long-Term Shareholder Value and Create Two Companies, Each a Leader in Its Respective Industry With Tailored Capital Allocation Priorities, Attractive Dividend Yield, and Meaningful Growth Opportunities Enhances Strategic and Financial Flexibility for Each Company Establishes UGI Corporation as a Premier Natural Gas Infrastructure Company Operating in Favorable U.S. Load-Growth Markets and Low-Cost Supply Regions New Global LPG Company Expected To Be The Largest Publicly Listed LPG Distribution Company in The World Following The Separation UGI Corporation to Host Conference Call and Webcast on Thursday, November 19, 2026, at 8:00 AM ET UGI Cor
UGI Reports Fiscal 2026 Results; Issues Fiscal 2027 Guidance
UGI Corporation (NYSE:UGI) today reported financial results for the fiscal year ended September 30, 2026 and provided guidance for fiscal year 2027. HEADLINES GAAP net income of $692 million and adjusted net income of $665 million compared to GAAP net income of $678 million and adjusted net income of $728 million in the prior year. GAAP diluted earnings per share ("EPS") of $3.12 and adjusted diluted EPS of $3.00 compared to GAAP diluted EPS of $3.09 and adjusted diluted EPS of $3.32 in the prior year. Delivered adjusted diluted EPS that exceeded our revised guidance range issued on May 6, 2026, inclusive of approximately $0.10 cents of incremental tax benefits associated with th
Millicom (Tigo) announces upsize and pricing of Senior Notes due 2033
Millicom (Tigo) announces upsize and pricing of Senior Notes due 2033 Luxembourg, November 18, 2026 – Millicom International Cellular S.A. ("Millicom") today announced the upsize and pricing of its private offering of 7.500% $900,000,000 Senior Notes due 2033 (the "Notes") that is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). Millicom expects to use the proceeds from the issuance of the Notes (i) to fund the purchase of any and all of Millicom’s outstanding 6.250% senior notes due 2029 (the "6.250% Notes") validly tendered and accepted for purchase in a concurrent tender offer (the "Tender Offer"), (ii) to redeem any 6.250% Note